Christopher Grunseich

Dr. Christopher Grunseich serves as a Lasker Clinical Research Scholar, Tenure Track Investigator, and head of the Inherited Neuromuscular Diseases Unit within the Neurogenetics Branch of the National Institutes of Health's Division of Intramural Research. As a physician-scientist board-certified in Neurology, he maintains an active clinical research program at the NIH Clinical Center in Bethesda, MD.

His educational background includes undergraduate training at Brown University, an M.D. from SUNY Stony Brook School of Medicine (2006), neurology residency at Georgetown University, and neurogenetics fellowship training with Dr. Kenneth Fischbeck at NIH. He progressed from Neurogenetics Fellow to Staff Clinician (2016) before receiving the prestigious Lasker Clinical Research Scholar award in 2024.

Dr. Grunseich's research focuses on translational approaches to inherited neuromuscular diseases, particularly spinal and bulbar muscular atrophy (SBMA) and genetic forms of ALS. His lab has made significant contributions to understanding R-loop dysregulation in neurodegeneration, developing patient-derived cellular models, and identifying molecular markers for clinical trials. The group employs innovative techniques including inducible transcription factor systems for motor neuron differentiation and advanced MRI-based efficacy measures.

Analysis of recent publications (2018-2023) reveals a clear research trajectory from fundamental molecular mechanisms (R-loop biology in ALS4) toward clinical applications (therapeutic trials in SBMA). The work consistently bridges basic science and patient-oriented research, with increasing emphasis on therapeutic development in later publications.

• Lasker Clinical Research Scholar (2024)

Dr. Grunseich oversees an active clinical research program with multiple ongoing studies, including investigations of exercise interventions and IGF-1 pathway agents for SBMA patients. His lab maintains strong translational focus with direct connections between molecular discoveries (e.g., SYNJ2BP-mediated mitochondrial-ER contacts) and clinical applications. The research program benefits from NIH intramural funding and access to specialized patient populations at the Clinical Center.

The Inherited Neuromuscular Diseases Unit comprises a biochemist/lab manager, clinical fellow, and multiple postbaccalaureate trainees working collaboratively on patient-derived cellular models, molecular marker development, and clinical trial execution. The lab's unique position within NIH enables direct translation of basic discoveries into therapeutic approaches for rare neuromuscular disorders.